Jefferies Healthcare Conference. Frank Witney, President & CEO
|
|
- Jesse Miller
- 5 years ago
- Views:
Transcription
1 Jefferies Healthcare Conference Frank Witney, President & CEO
2 Forward Looking Statement This presentation contains statements that are "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of These statements involve risks and uncertainties that could cause our actual results to differ materially from the future results expressed or implied by the forward-looking statements. All statements other than statements of historical facts included in this presentation, including statements regarding our future financial position and results, are forward-looking statements. For further information regarding risks and uncertainties associated with our business, please refer to our SEC filings, including, but not limited to, the Risk Factors section of our SEC filings, including without limitation our annual report on Form 10-K and quarterly reports. Forward-looking statements are made as of June 3, 2015 and the Company assumes no obligation and expressly disclaims any duty to update this information. 2
3 Our Strategic Roadmap Realigned and expanded product portfolio for translational medicine and clinical diagnostics Return to growth Reduce cost structure Drive profitability & strengthen balance sheet Profitable and growing Expand translational medicine and clinical diagnostic franchises Strong balance sheet & strategic flexibility Phase I Phase II Phase III
4 The Right Tool for the Job Reproductive Health Cyto and NIPT Genetic variants (SNP, CNV) Expression analysis (RNA, Protein, Pathway) Cancer Genomics Genotyping Biobanks Single-cell analysis Functional analysis Single Cell Biology Flow cytometry Molecular Pathology Integrated molecular and cellular view with clinical data 4
5 Development & Application Priorities Translational Medicine & Molecular Dx Genotyping Single Cell Biology Whole genome cytogenetics Reproductive Health Cancer RNA biomarkers Biobanks Ag Bio HLA Flow cytometry reagents Multiplex immunoassays Molecular pathology (RNA-ISH) Pharmacogenomics Microbiome Pharmacogenomics Wellness & DTC Single cell genomics Molecular pathology (RNA-ISH) 5
6 Growth Drivers in Genotyping Biobanks Large-scale genetic analysis Highly flexible, rapid and cost effective customization Photolithographic manufacturing reduces batchto-batch variation Fully automated highthroughput workflow enables large projects AgBio Rapid adoption of genetic tools for genomic selection / trait improvements New 384-format Axiom increases throughput and lowers cost Recurring revenues that are not subject to academic funding Represents ~ 25% of our genotyping revenues 6
7 Acquisition of Eureka Genomics Announced acquisition of Eureka Genomics for $15 million in cash Established in 2008 using flexible & cost-effective technology developed at the University of Houston Early stage business leveraging an innovative SNP assay with NGSbased detection that can support both service and product kits Compliments our genotyping portfolio with low-plex applications that can leverage the large installed base of NGS instrumentation Addresses the largely under-served market for low-plex agrigenomics Clear synergies with our global commercial channel and manufacturing 7
8 Broad Menu of AgBio Applications Enabled by Eureka Genomics Technology <100 SNPs Traceability & QC Eureka Assay Low 00s SNPs Parentage 500 SNPs Marker Assisted Management SNPs Imputationpowered Affordable Genomic Selection
9 LowPlex AgBio Market is a Significant Growth Opportunity with a CAGR of ~ 25% Low-Plex (100 s-few 1,000 s) AgBio SAM Med-high-Plex (few 1,000 s-few 100,000 s) AgBio SAM SAM 2014 SAM 2017 $50M $98M $110 M $210M Segment size, $ Millions * Sources: MacQuarie, 9 Cowen and BCC
10 Expands our Genetic Analysis Portfolio FY % 6% 21% 7% 40% Expression Life Sci. Reagents ebioscience Genetic Analysis Corporate 10
11 Growth Drivers for Reproductive Health Post Natal Cytogenetics We now have more than 350 active accounts New Growth Opportunities Ariosa Diagnostics has migrated their industry-leading Harmony Prenatal test to an array-based approach from Affymetrix in January of 2015 The NIPT market is forecast to grow to approximately $4.8 billion by 2018* A recent study of 19K patients demonstrated that cell free DNA testing was superior to traditional first trimester screening for the detection of trisomy 21, regardless of age or risk status 11 * - reference JPM NGS Deep Dive report
12 Growth Drivers for Single Cell Biology 1. Expected to grow into a $1B Market by What s the unmet need? Bulk analysis of heterogeneous cells masks relevant events Cells with identical genomes can have different cellular traits Goal is to understand individual cells in context, not an average 3. Convergence of proteomic and genomic analysis applied at the single cell level is a funding mega-trend with strong translational and clinical market pull 12
13 A Portfolio of Tools for Single Cell Biology ISOLATION AMPLIFICATION (cdna library prep) OMIC ANALYSIS Flow cytometry GeneChip WT Pico Reagent Kit Microarray SINGLE CELL VALIDATION 13 QG View Tissue PrimeFlow RNA QG ViewCell RNA
14 Improved Growth, Profitability & Cash Metric Q Q Delta Total Revenue $88.7M $82.9M 6.9% *Adjusted EBITDA $17.1M $12.9M 33% *Non-GAAP Net income $7.9M $1.9M $6M *Non-GAAP EPS $0.10 $0.03 $0.07 Cash & Securities $104M $58M 79% Senior Debt $22M $36M 39% * See published reconciliations to GAAP results 14
15 Summary In Phase II of our strategic plan we returned company to growth, profitability and strengthened our balance sheet In Phase III we are focused on generating durable growth in our core markets of Reproductive Health Human and AgBio Genotyping Single Cell Biology In FY15 we expect to grow our total revenues in the midsingle digit range on a constant currency basis We will our use our strengthened balance sheet to execute on tuck in acquisitions to stimulate growth in our verticals 15
16 Thank you
JP Morgan. Global Healthcare Conference. Robert Friel, Chairman and CEO January 11, PerkinElmer
JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 11, 2017 2016 PerkinElmer Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking"
More informationPerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH
PerkinElmer, Inc JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP
More informationJ.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018
J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018 Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationJP Morgan Global Healthcare Conference
JP Morgan Global Healthcare Conference January 12, 2016 Robert Friel, Chairman and CEO Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements
More informationJ.P. MORGAN Health Conference. Robert Friel Chairman and CEO January 9, 2019
J.P. MORGAN Health Conference Robert Friel Chairman and CEO January 9, 2019 Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements which
More information2019 JP Morgan Healthcare Conference
2019 JP Morgan Healthcare Conference Francis desouza President & CEO January 7, 2019 2019 Illumina, Inc. All rights reserved. Safe Harbor Statement This communication may contain statements that are forward-looking.
More informationHigh Cross-Platform Genotyping Concordance of Axiom High-Density Microarrays and Eureka Low-Density Targeted NGS Assays
High Cross-Platform Genotyping Concordance of Axiom High-Density Microarrays and Eureka Low-Density Targeted NGS Assays Ali Pirani and Mohini A Patil ISAG July 2017 The world leader in serving science
More informationPerkinElmer, Inc. Andy Wilson, CFO May 13, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH. Bank of America Merrill Lynch Global Healthcare Conference
PerkinElmer, Inc Bank of America Merrill Lynch Global Healthcare Conference Andy Wilson, CFO May 13, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP
More informationNon Deal Roadshow - Europe
Non Deal Roadshow - Europe 2015 May Analyst Meeting February/March 2016 The world leader in serving science The world leader in serving science Non-GAAP Measures This presentation contains certain financial
More informationTecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA
Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical
More informationIllumina Diagnostics. Emily Winn-Deen, PhD Vice President, Product Development Diagnostics
Introduction ti to Illumina Diagnostics Emily Winn-Deen, PhD Vice President, Product Development Diagnostics 2010 Illumina, Inc. All rights reserved. Illumina, illuminadx, Solexa, Making Sense Out of Life,
More informationAgilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks
Agilent Technologies First Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2017. With me
More informationRedefine what s possible with the Axiom Genotyping Solution
Redefine what s possible with the Axiom Genotyping Solution From discovery to translation on a single platform The Axiom Genotyping Solution enables enhanced genotyping studies to accelerate your research
More informationILLUMINA SEQUENCING SYSTEMS
ILLUMINA SEQUENCING SYSTEMS PROVEN QUALITY. TRUSTED SOLUTIONS. Every day, researchers are using Illumina next-generation sequencing (NGS) systems to better understand human health and disease, as well
More informationTitelstijl van model bewerken
Generate Titelstijl van and verify model your bewerken data Solutions for all your genetic analysis needs Sanger Sequencing Microarray technology QuantStudio real-time and digital PCR Ion Torrent NGS systems
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationAKESOgen, Inc, 3155 Northwoods Place, NW, Norcross, GA 30071, USA Tel: +1 (770) Page 1
Page 1 HLA Sequencing Based Typing Workflow: A- Sample Collection: iswab-discovery (Mawi DNA Technologies) - Sample was transported by standard US postal services mail, no cold chain of any sort was involved
More informationAgilent Technologies First Quarter Fiscal 2019 Conference Call Prepared Remarks
Agilent Technologies First Quarter Fiscal 2019 Conference Call Prepared Remarks ANKUR DHINGRA Thank you, and welcome everyone to Agilent's First Quarter Conference Call for Fiscal Year 2019. With me are
More information2018 RW Baird Health Care Conference. September 5 th, 2018
2018 RW Baird Health Care Conference September 5 th, 2018 1 Forward-looking Statements This presentation and the accompanying oral commentary contain forward -looking statements that involve risks, uncertainties
More informationFluidigm Corporation. Q4 and Full Year March, 2019
Fluidigm Corporation Q4 and Full Year 2018 March, 2019 Use of forward-looking statements, trademarks This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationJEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER
JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER SAFE HARBOR STATEMENT Certain statements made during the course of this presentation may
More informationIntroducing QIAseq. Accelerate your NGS performance through Sample to Insight solutions. Sample to Insight
Introducing QIAseq Accelerate your NGS performance through Sample to Insight solutions Sample to Insight From Sample to Insight let QIAGEN enhance your NGS-based research High-throughput next-generation
More informationAgilent NGS Solutions : Addressing Today s Challenges
Agilent NGS Solutions : Addressing Today s Challenges Charmian Cher, Ph.D Director, Global Marketing Programs 1 10 years of Next-Gen Sequencing 2003 Completion of the Human Genome Project 2004 Pyrosequencing
More informationThe first and only fully-integrated microarray instrument for hands-free array processing
The first and only fully-integrated microarray instrument for hands-free array processing GeneTitan Instrument Transform your lab with a GeneTitan Instrument and experience the unparalleled power of streamlining
More informationAgilent Technologies. Q2 15 Results Presentation. Page 1
Agilent Technologies Q2 15 Results Presentation Page 1 Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company s
More informationCorporate Presentation. September 6th, 2018
Corporate Presentation September 6th, 2018 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationBD Strategy Overview. Advancing the world of health. Vincent A. Forlenza Chairman, Chief Executive Officer and President
BD Strategy Overview Advancing the world of health Vincent A. Forlenza Chairman, Chief Executive Officer and President BD IS AT THE VERY BEGINNING OF AN AMAZING JOURNEY WHERE WE CAN HAVE A PROFOUND IMPACT
More informationGene expression microarrays and assays. Because your results can t wait
Gene expression microarrays and assays Because your results can t wait A simple path from data to decision-making The power of expression microarrays Transcriptome-wide analysis can be complex. Matching
More informationCorporate Presentation. February 2, 2018
Corporate Presentation February 2, 2018 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationAgilent Genomics Software Future Directions
Agilent Genomics Software Future Directions Michael Rosenberg, PhD Director, Genomics Software Agilent: A Focused Measurement Company Serving Diverse End Markets Electronic Measurement 2008 Revenue: $3.6
More informationInvitae Corporation (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 12, 2018 (Date
More informationMassARRAY Genetic Analysis System. Genotyping Methylation Analysis Molecular Typing Somatic Mutation Profiling Quantitative Gene Expression (QGE)
MassARRAY Genetic Analysis System Genotyping Methylation Analysis Molecular Typing Somatic Mutation Profiling Quantitative Gene Expression (QGE) MassARRAY Genetic Analysis System * Overview Next-generation
More informationSingle Cell Genomics (SCG): Market Size, Segmentation, Growth, Competition and Trends ( )
Single Cell Genomics (SCG): Market Size, Segmentation, Growth, Competition and Trends (2013-2021) May, 2017 3 rd Edition Information contained in this market report is believed to be reliable at the time
More informationAgilent Technologies. Q4'18 Results Presentation
Agilent Technologies Q4'18 Results Presentation Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company s goals,
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationAnnual Meeting of Shareholders January 22, 2019
Annual Meeting of Shareholders January 22, 2019 Vincent A. Forlenza Chairman and Chief Executive Officer Becton, Dickinson and Company Forward-looking statements These materials include forward-looking
More information36 th Annual JP Morgan Healthcare Conference. January 11 th, 2018
36 th Annual JP Morgan Healthcare Conference January 11 th, 2018 1 Forward-looking Statements This presentation and the accompanying oral commentary contain forward -looking statements that involve risks,
More informationAgilent Technologies Fourth Quarter Fiscal 2017 Conference Call Prepared Remarks
Agilent Technologies Fourth Quarter Fiscal 2017 Conference Call Prepared Remarks ALICIA RODRIGUEZ Thank you, and welcome everyone to Agilent's Fourth Quarter Conference Call for Fiscal Year 2017. With
More informationInvestor Presentation
Investor Presentation 2018 www.enzo.com LEGAL DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward-looking" statements within the meaning of Section 27A
More informationCapabilities & Services
Capabilities & Services Accelerating Research & Development Table of Contents Introduction to DHMRI 3 Services and Capabilites: Genomics 4 Proteomics & Protein Characterization 5 Metabolomics 6 In Vitro
More informationAxiom Biobank Genotyping Solution
TCCGGCAACTGTA AGTTACATCCAG G T ATCGGCATACCA C AGTTAATACCAG A Axiom Biobank Genotyping Solution The power of discovery is in the design GWAS has evolved why and how? More than 2,000 genetic loci have been
More informationBio-Rad Laboratories, Inc. Investor Day 2017
Bio-Rad Laboratories, Inc. Investor Day 2017 Welcome Norman Schwartz Chairman of the Board, Chief Executive Officer Forward-Looking Statements Some statements in this presentation may be forward-looking
More informationDNA. Clinical Trials. Research RNA. Custom. Reports CLIA CAP GCP. Tumor Genomic Profiling Services for Clinical Trials
Tumor Genomic Profiling Services for Clinical Trials Custom Reports DNA RNA Focused Gene Sets Clinical Trials Accuracy and Content Enhanced NGS Sequencing Extended Panel, Exomes, Transcriptomes Research
More information35th Annual J.P. Morgan Healthcare Conference
35th Annual J.P. Morgan Healthcare Conference Investor Presentation Nachum Homi Shamir President and Chief Executive Officer January, 2017 Safe Harbor Statement Certain statements made during the course
More informationE2ES to Accelerate Next-Generation Genome Analysis in Clinical Research
www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution
More informationMolecular Diagnostics
Molecular Diagnostics Positioning the Laboratory for the Future Through Scalable Lab Developed Test Workflows, Clinical-level Quality, & Operational Efficiency Path to the heart of healthcare Change It
More information2017 Annual Meeting of Shareholders
2017 Annual Meeting of Shareholders May 17, 2017 The world leader in serving science Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following presentations about the company s
More informationNGS-based innovations within the Leiden Network
NGS-based innovations within the Leiden Network A strong bridge between two partners Dr. Mark de Jong 2017-09-29 Design accurate and robust NGS tests and generate data sets essential for Diagnostics &
More informationQIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd
QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd 1 Our current NGS & Bioinformatics Platform 2 Our NGS workflow and applications 3 QIAGEN s
More informationAIT - Austrian Institute of Technology
BIOMARKER DISCOVERY, BIOINFORMATICS, AND BIOSENSOR DEVELOPMENT Technology Experience AIT Austrian Institute of Technology Low-Emission Transport AIT - Austrian Institute of Technology Energy Health & Bioresources
More informationPioneering Clinical Omics
Pioneering Clinical Omics Clinical Genomics Strand NGS An analysis tool for data generated by cutting-edge Next Generation Sequencing(NGS) instruments. Strand NGS enables read alignment and analysis of
More informationIntroducing combined CGH and SNP arrays for cancer characterisation and a unique next-generation sequencing service. Dr. Ruth Burton Product Manager
Introducing combined CGH and SNP arrays for cancer characterisation and a unique next-generation sequencing service Dr. Ruth Burton Product Manager Today s agenda Introduction CytoSure arrays and analysis
More informationUnlocking the Power of the Genome
Unlocking the Power of the Genome Sam Samad, Chief Financial Officer William Blair Growth Stock Conference, 13 June 2018 2018 Illumina, Inc. All rights reserved. Safe Harbor Statement This presentation
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationGenomic solutions for complex disease
Genomic solutions for complex disease Power your with our genomic solutions Access a breadth of applications. Gain a depth of insights. To enhance their understanding of complex disease, researchers are
More informationWELCOME. Norma J. Nowak, PhD Executive Director, NY State Center of Excellence in Bioinformatics and Life Sciences (CBLS)
WELCOME Norma J. Nowak, PhD Executive Director, NY State Center of Excellence in Bioinformatics and Life Sciences (CBLS) Director, UB Genomics and Bioinformatics Core (GBC) o o o o o o o o o o o o Grow
More informationBiomarkers in Biochips and Microarrays: Innovative Technologies, Growth Opportunities and Future Market Outlook
Biomarkers in Biochips and Microarrays: Innovative Technologies, Growth Opportunities and Future Market Outlook Introduction The report provides a strategic insight into the use of biomarkers in biochip
More informationHill-Rom: Acquiring Mortara Instrument Complementary Combination Strengthens Clinical Focus on Diagnostic Cardiology and Patient Monitoring
Hill-Rom: Acquiring Mortara Instrument Complementary Combination Strengthens Clinical Focus on Diagnostic Cardiology and Patient Monitoring January 10, 2017 Forward Looking Statements This presentation
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More information30 th Annual JP Morgan Healthcare Conference January 10, Carl Hull, Chairman and CEO Herm Rosenman, SVP and CFO
An Innovative Growth Company in Molecular Diagnostics 30 th Annual JP Morgan Healthcare Conference January 10, 2012 Carl Hull, Chairman and CEO Herm Rosenman, SVP and CFO Safe Harbor Statement Any statements
More informationDNA Microarray Technology
CHAPTER 1 DNA Microarray Technology All living organisms are composed of cells. As a functional unit, each cell can make copies of itself, and this process depends on a proper replication of the genetic
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationMagnis NGS Prep System. Your lab s automated library preparation solution for next-generation sequencing
Magnis NGS Prep System Your lab s automated library preparation solution for next-generation sequencing Magnis NGS Prep System Complete system for NGS preparation One of the challenges with implementing
More informationTriNet Group, Inc. Investor Presentation March 2018
TriNet Group, Inc. Investor Presentation March 2018 Disclaimer Cautionary Note Regarding Forward-Looking Statements and Other Financial Information This presentation contains statements that are not historical
More informationQiagen N.V. (QIA) - Financial and Strategic SWOT Analysis Review
Qiagen N.V. (QIA) - Financial and Strategic SWOT Analysis Review Qiagen N.V. (QIA) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports from
More informationNext Generation Sequencing (NGS) Market Size, Growth and Trends ( )
Next Generation Sequencing (NGS) Market Size, Growth and Trends (2014-2020) July, 2017 4 th edition Information contained in this market report is believed to be reliable at the time of publication. DeciBio
More informationGenomics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Genomics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Increasing usage of novel genomics techniques and tools, evaluation of their benefit to patient outcome and focusing
More informationInvestor Presentation. November 2016
Investor Presentation November 2016 Safe Harbor Statement The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, events or performance
More informationCorporate Overview. December Erik Holmlin President & CEO
Corporate Overview December 2018 Erik Holmlin President & CEO Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements describe future expectations,
More informationDisclaimer Forward-Looking Statements Industry and Market Data Non-GAAP Financial Information
Disclaimer Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Securities Act of 1933, as amended (the Securities Act ), the Securities Exchange Act
More informationBruker drives profitable growth by enabling breakthrough discoveries & development of new applications that improve the quality of human life
Bruker drives profitable growth by enabling breakthrough discoveries & development of new applications that improve the quality of human life Innovation with Integrity BRUKER CORPORATION Safe Harbor Statement
More informationPrecision Engineered Products Acquisition August 17, 2015
Precision Engineered Products Acquisition August 17, 2015 Forward-Looking Statements and Non-GAAP Financial Information Forward Looking Statements: With the exception of the historical information contained
More informationTECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298
DIAGNOSTICS BUSINESS ANALYSIS SERIES: TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 By ADAMS BUSINESS ASSOCIATES March 2017. March 2017 ABA 298 1 Technologies, Products & Services
More informationTHE FREEDOM TO DISCOVER BOND RX FULLY AUTOMATED IHC AND ISH AND EMERGING TESTS RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
BOND RX FULLY AUTOMATED IHC AND ISH AND EMERGING TESTS RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. EXPLORE YOUR IDEAS PUSH THE BOUNDARIES OF WHAT IS POSSIBLE The BOND RX fully automated research
More informationBUILDING BETTER SCIENCE
BUILDING BETTER SCIENCE AGILENT AND YOU ACADEMIC & INSTITUTIONAL RESEARCH ENRICH DISCOVER SUPPORT STIMULATE AGILENT IN ACADEMIA: DRIVEN TO CONNECT Academia is a highly interactive and interdisciplinary
More informationWILLIAM BLAIR GROWTH STOCK CONFERENCE. June 14, 2017
WILLIAM BLAIR GROWTH STOCK CONFERENCE June 14, 2017 Safe Harbor Statement Statements made in this presentation which are not statements of historical fact are forward-looking statements and are subject
More informationSample to Insight. Dr. Bhagyashree S. Birla NGS Field Application Scientist
Dr. Bhagyashree S. Birla NGS Field Application Scientist bhagyashree.birla@qiagen.com NGS spans a broad range of applications DNA Applications Human ID Liquid biopsy Biomarker discovery Inherited and somatic
More informationInvestor Presentation
Investor Presentation 2017 www.enzo.com LEGAL DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward looking" statements within the meaning of Section 27A
More informationMegan Schmidt Vice President of Product Management, CompuGroup Medical
Thursday April 6, 2017 A01 Molecular and Genetic Testing: How to Position your Laboratory for New Technology Megan Schmidt Vice President of Product Management, CompuGroup Medical DESCRIPTION: Molecular
More informationForward looking statements
Update on QIAensemble strategy May 8, 2011-1 - Sample & Assay Technologies Forward looking statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forwardlooking
More informationWelcome to Synchronoss 3.0
Welcome to Synchronoss 3.0 Intralinks Acquisition Overview and Activation Divestiture December 6, 2016 1 2016 Synchronoss, Inc. All Rights Reserved Safe Harbor. Forward-Looking Statements This presentation
More informationLiquidBiopsy LIQUIDBIOPSY. Automated Rare Template Isolation Platform
LiquidBiopsy LIQUIDBIOPSY Automated Rare Template Isolation Platform Enabling cancer research with highly multiplexed molecular analysis of serially collected blood samples The LiquidBiopsy Platform simplifies
More informationIon S5 and Ion S5 XL Systems
Ion S5 and Ion S5 XL Systems Targeted sequencing has never been simpler Explore the Ion S5 and Ion S5 XL Systems Adopting next-generation sequencing (NGS) in your lab is now simpler than ever The Ion S5
More informationIntroducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration
Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration 1 2 Translational Informatics Overview Precision s suite of services is
More information$3bn ~4% pa $5bn 5-8% pa
Leadership in research use markets is strengthening our competitive position in an $8bn addressable market Estimated Total Addressable Markets $3bn ~4% pa $5bn 5-8% pa 1 2 Research Use (RUO) Proteomic
More informationMolecular Diagnostics: Market Segmentation and Opportunities
Molecular Diagnostics: Market Segmentation and Opportunities October 2010 This market report is published by DeciBio, LLC. All rights reserved. Reproduction or redistribution of this report in any form
More informationTriNet Group, Inc. Investor Presentation August September 2018
TriNet Group, Inc. Investor Presentation August September 2018 Disclaimer Cautionary Note Regarding Forward-Looking Statements and Other Financial Information This presentation contains statements that
More informationGlobalSpec Acquisition. Supplemental Deck June 12, 2012
GlobalSpec Acquisition Supplemental Deck June 12, 2012 1 Safe harbor Statements in this presentation that are not reported financial results or other historical information are forward-looking statements
More informationR1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business
R1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business Investor Presentation February 26, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation
More informationAgrigenomics Genotyping Solutions. Easy, flexible, automated solutions to accelerate your genomic selection and breeding programs
Agrigenomics Genotyping Solutions Easy, flexible, automated solutions to accelerate your genomic selection and breeding programs Agrigenomics genotyping solutions A single platform for every phase of your
More informationFrequently asked questions
Frequently asked questions Affymetrix Mouse Diversity Genotyping Array The Affymetrix Mouse Diversity Genotyping Array features more than 623,000 single nucleotide polymorphisms (SNPs) and more than 916,000
More informationJohn Harper. Dell Investor Relations See for more information
Michael Dell Ross Perot Jr. Chairman and CEO, Dell Chairman, Perot Systems Brian Gladden Peter Altabef Senior Vice President and CFO, Dell President and CEO, Perot Systems John Harper September 21, 2009
More informationBR-10455A. Automated Multiplexed Gene Expression Profiling Process Solutions. Multiplex Quantitative High-throughput
BR-10455A Automated Multiplexed Gene Expression Profiling Process Solutions Multiplex Quantitative High-throughput As a scientist, you understand the challenges of working with limited amounts of sample,
More informationTotal genomic solutions for biobanks. Maximizing the value of your specimens.
Total genomic solutions for biobanks. Maximizing the value of your specimens. Unlock the true potential of your biological samples. Greater understanding. Increased value. Value-driven biobanking. Now
More informationTrimble Third Quarter 2017 Results Summary
Trimble Third Quarter 2017 Results Summary Forward-looking statements Certain statements made in this presentation and any subsequent Q&A period are forward -looking statements, within the meaning of Section
More informationASHG 2018 CoLab Schedule CoLab #1 Booth #1441 DATA CLINICAL LABORATORY OTHER NO COLAB
ASHG 2018 CoLab Schedule CoLab #1 Booth #1441 DATA CLINICAL LABORATORY OTHER NO COLAB Wed. Sponsor Topic Thursday Sponsor Topic Friday Sponsor Topic 10:00 am 10:30 am Covaris Standardization of the ChIP
More information